Alternaturals, Inc.
ANAS · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 1.24 | 1.35 | -0.03 |
| FCF Yield | 0.00% | -7.41% | -0.77% | -11.75% |
| EV / EBITDA | -84.90 | -63.86 | -130.36 | -8.27 |
| Quality | ||||
| ROIC | -20.50% | -23.02% | 0.00% | 0.00% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 4.59 | 1.00 | 0.97 | 0.72 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | 0.00% | -156.11% | 93.63% | -1,672.47% |
| Safety | ||||
| Net Debt / EBITDA | -3.27 | -2.02 | -1.00 | -0.03 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |